Inflammatory bowel disease
Test in Focus
Inflammatory bowel disease (IBD) serology testing at Mayo Clinic Laboratories can help physicians distinguish between an ulcerative colitis diagnosis and a Crohn’s disease diagnosis. Melissa Snyder, Ph.D., explains in a “Test in Focus” episode of the “Answers From the Lab” podcast how the IBDP2 serology panel can make this important distinction after first-line testing has failed.
The IBDP2 serology panel investigates the presence of antibodies against Saccharomyces cerevisiae IgA and IgG, and anti-neutrophil cytoplasmic antibodies (pANCA) to confirm disease presence in patients with an unclear diagnosis.
“Inflammatory bowel disease can be a difficult diagnosis,” says Dr. Snyder. “We certainly know a lot about the genetics of IBD, but we do not have a strong genetic marker. There are a lot of contributing genes that lead to the development of IBD.”
Dr. Synder explains where the IBDP2 panel may come into the diagnostic process for IBD. “First there is a screen for fecal calprotectin. If it is elevated, then imaging is performed, and pathologic analysis, and if that is still not giving you the information you need and there is a suspicion for IBD, then the IBDP2 panel may be helpful in those patients.”
With this test offering from Mayo Clinic Laboratories, physicians can obtain reliable results to help them make a definitive diagnosis. “The serology test is most useful in a subset of patients where the physician is fairly certain IBD is the correct diagnosis, but it may be unclear if it is ulcerative colitis or Crohn’s disease,” says Dr. Snyder.